Underuse of erythropoiesis-stimulating agents (ESA) and ESA hyporesponsiveness are 2 important reasons for red blood cell transfusion, according to a recent review.
WASHINGTON—Dapagliflozin may correct anemia in patients with type 2 diabetes and chronic kidney disease (CKD), study findings presented at the American Society of Nephrology’s Kidney Week 2019 suggest. Bergur V. Stefansson, MD, PhD, of AstraZeneca in Gothenburg, Sweden, and colleagues analyzed pooled data from 5325 patients who had participated in 14 double-blind randomized trials comparing…
In a 12-week head-to-head study, ferric citrate significantly increased ferritin and hemoglobin levels, whereas ferrous sulfate did not, investigators reported.
WASHINGTON—Functional iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD) is associated with an increased risk for death and cardiovascular-related hospitalization, according to study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting. Absolute IDA is associated with an elevated risk of hospitalization. A team at Baylor College of Medicine…
In phase 3 trials, the drug raised hemoglobin better than epoetin alfa, with improved CV safety.
Greater annual declines in residual kidney function during the first year on hemodialysis are associated with increasing odds of anemia, study finds.
In a phase 2 trial of hemodialysis patients resistant to erythropoietin, inhibition of the proinflammatory cytokine interleukin-6 with the monoclonal antibody ziltivekimab decreased inflammatory markers, increased hemoglobin, decreased ESA requirements and increased serum albumin.
In a large cohort of patients with chronic kidney disease not on dialysis, 23.3% of patients had hemoglobin levels below 10 g/dL at baseline.
WASHINGTON—Obesity is associated with a lower risk of anemia among patients with chronic kidney disease (CKD), investigators reported at the American Society of Nephrology’s Kidney Week 2019 meeting. The finding is from a prospective study that included 2214 patients in the KNOW-CKD (KoreaN Cohort Study for Outcome in Patients with Chronic Kidney Disease) study. During…
Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa.